Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England

Autor: Vishal Patel, Bethany Levick, Stephen Boult, Daniel C. Gibbons, Myriam Drysdale, Emily J. Lloyd, Moushmi Singh, Helen J. Birch

Publikováno v: BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-8 (2024)

Abstract Background The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outc

Externí odkaz: https://doaj.org/article/9ffce5c4ddc843bca1345684dccb61e5

Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review

Autor: Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, Catherine Rolland, Louis Lavoie, Andrew Skingsley, Emily J. Lloyd

PurposeEmerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have impacted the in vitro activity of sotrovimab 500 mg, with reduced fold change in EC50for the Omicron BA.2 sublineage and onward. The correlation between this r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eade6792844fb85555a18da202e9c65c
https://doi.org/10.1101/2023.03.09.23287034

Fractures in untreated patients with osteoporosis in Germany: an InGef healthcare insurance database analysis

Autor: E. Dornstauder, G Worth, Moushmi Singh, Artak Khachatryan, Indraraj Umesh Doobare, Wolfgang Böcker, D.A. Kahangire, Robert Bartsch

Publikováno v: Osteoporosis International. 33:77-86

Osteoporosis is a skeletal disease that may result in low-trauma fracture if untreated. Among men and women ≥ 70 years untreated for osteoporosis, 30% (43,514) sustained at least one post-index fracture. Care for patients with osteoporosis diagnosi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2d9a41387eeb85d2162de4058dfadd0
https://doi.org/10.1007/s00198-021-06051-w

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)

Autor: Jean-Vannak Chauny, Jie Meng, Heng Jiang, Cyrille Touzeau, Nadia Quignot, Moushmi Singh, Vanessa Taieb, Gaëlle Désaméricq, Artak Khachatryan

Publikováno v: Annals of Hematology
Annals of Hematology, 2021, 100 (7), pp.1825-1836. ⟨10.1007/s00277-021-04522-y⟩
Annals of Hematology, Springer Verlag, 2021, 100 (7), pp.1825-1836. ⟨10.1007/s00277-021-04522-y⟩

Over the past decade, several drugs have been approved for the treatment of relapsed or refractory multiple myeloma (RRMM). This retrospective study, using the French National Healthcare database (SNDS), describes the treatment patterns and outcomes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2eb1f9924a91c84d0cfc168d60144c
https://www.hal.inserm.fr/inserm-03349226

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

Autor: Monika Engelhardt, Achim Rieth, Andrea Lebioda, Sebastian Gonzalez-McQuire, Martina Schoehl, Moushmi Singh, Tilman Hans Steinmetz, Leah Fink

Publikováno v: Journal of medical economics. 24(1)

To assess the real-world healthcare resource utilization (HRU) and costs associated with different proteasome inhibitors (PIs) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM) in Germany. We conducted a retrospect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be9a23c40d628072fcc08c17be99f41
https://pubmed.ncbi.nlm.nih.gov/33390079